Entera Bio’s (ENTX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Entera Bio (NASDAQ:ENTX) in a research note published on Friday morning, Benzinga reports. The brokerage currently has a $10.00 price target on the stock.

Entera Bio Stock Up 4.7 %

Shares of NASDAQ ENTX opened at $2.01 on Friday. The company has a market capitalization of $71.93 million, a PE ratio of -7.18 and a beta of 1.57. The firm has a fifty day simple moving average of $1.76 and a 200 day simple moving average of $1.94. Entera Bio has a twelve month low of $0.52 and a twelve month high of $3.35.

Entera Bio (NASDAQ:ENTX) last announced its quarterly earnings data on Friday, August 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.06). The business had revenue of $0.06 million during the quarter. As a group, equities analysts expect that Entera Bio will post -0.23 earnings per share for the current fiscal year.

Institutional Trading of Entera Bio

A hedge fund recently bought a new stake in Entera Bio stock. Virtu Financial LLC bought a new stake in shares of Entera Bio Ltd. (NASDAQ:ENTX) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 22,040 shares of the company’s stock, valued at approximately $37,000. Hedge funds and other institutional investors own 14.11% of the company’s stock.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.